NASDAQ: BDRXBiodexa Pharmaceuticals PLC Stock
$0.73-0.02 (-2.67%)
Updated Apr 25, 2024
Biodexa shares are trading higher... find out Why BDRX Price Moved with a free WallStreetZen account
Why Price MovedBDRX Price
$0.73
Fair Value Price
N/A
Market Cap
$3.70M
52 Week Low
$0.67
52 Week High
$21.38
P/E
-0.07x
P/B
0.64x
P/S
3.86x
PEG
N/A
Dividend Yield
N/A
Revenue
$470.37k
Earnings
-$8.96M
Gross Margin
100%
Operating Margin
-1,953.81%
Profit Margin
-1,858%
Debt to Equity
1.25
Operating Cash Flow
-$10M
Beta
0.63
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BDRX Overview
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BDRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BDRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BDRX is good value based on its book value relative to its share price (0.64x), compared to the US Biotechnology industry average (5.8x)
P/B vs Industry Valuation
BDRX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BDRX due diligence checks available for Premium users.
Be the first to know about important BDRX news, forecast changes, insider trades & much more!
BDRX News
Valuation
BDRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.07x
Industry
15.41x
Market
40.97x
BDRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.64x
Industry
5.8x
BDRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BDRX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
BDRX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BDRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$13.3M
Liabilities
$7.4M
Debt to equity
1.25
BDRX's short-term assets ($8.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BDRX's short-term assets ($8.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BDRX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BDRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
BDRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BDRX vs Biotech Stocks
Biodexa Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.